Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24159230 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL24802750 | 0.76 | SMN1; SMN2 (0.31) | PIK3CDCYP3A4 | |
| SCHEMBL21576549 | 0.76 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL22193066 | 0.76 | SMN1; SMN2 (0.37) | PIK3CD | |
| SCHEMBL21675901 | 0.75 | GAA (0.33) | PIK3CDCYP3A4 | |
| SCHEMBL3478137 | 0.75 | GAA (0.33) | PIK3CDCYP3A4 | |
| SCHEMBL21688341 | 0.75 | GAA (0.33) | PIK3CDCYP3A4 | |
| Hydrochloric Acid SCHEMBL21570154 | 0.75 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL25378830 | 0.72 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL19159637 | 0.72 | DRD3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PIK3CD 831/4885CYP3A4 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.